HRTX logo

HRTX
Heron Therapeutics Inc

7,338
Mkt Cap
$159.96M
Volume
765,316.00
52W High
$2.30
52W Low
$0.7362
PE Ratio
-4.79
HRTX Fundamentals
Price
$0.8771
Prev Close
$0.8451
Open
$0.8419
50D MA
$0.9528
Beta
1.45
Avg. Volume
1.96M
EPS (Annual)
-$0.1211
P/B
19.71
Rev/Employee
$1.21M
$311.78
Loading...
Loading...
News
all
press releases
Why Heron Therapeutics, Inc. (HRTX) Price Target Was Reduced to $4 at H.C. Wainwright?
Why Heron Therapeutics, Inc. (HRTX) Price Target Was Reduced to $4 at H.C. Wainwright...
Yahoo! Finance: News·2d ago
News Placeholder
More News
News Placeholder
Heron Therapeutics Q1 Earnings Call Highlights
Heron Therapeutics Q1 Earnings Call Highlights...
Yahoo! Finance: News·10d ago
News Placeholder
Heron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Heron Therapeutics (HRTX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks·10d ago
News Placeholder
Heron Therapeutics (HRTX) Reports Q1 Loss, Lags Revenue Estimates
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -33.33% and -3.91%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·10d ago
News Placeholder
Ironwood Pharmaceuticals (IRWD) Tops Q1 Earnings and Revenue Estimates
Ironwood (IRWD) delivered earnings and revenue surprises of +242.86% and +44.26%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·14d ago
News Placeholder
electroCore, Inc. (ECOR) Reports Q1 Loss, Beats Revenue Estimates
electroCore (ECOR) delivered earnings and revenue surprises of -0.86% and +7.14%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·15d ago
News Placeholder
Earnings Preview: ARS Pharmaceuticals, Inc. (SPRY) Q1 Earnings Expected to Decline
ARS Pharmaceuticals, Inc. (SPRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·15d ago
News Placeholder
Analysts Estimate Heron Therapeutics (HRTX) to Report a Decline in Earnings: What to Look Out for
Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·17d ago
News Placeholder
Heron Therapeutics (HRTX) Expected to Announce Quarterly Earnings on Tuesday
Heron Therapeutics (NASDAQ:HRTX) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 5. (View Earnings Report at...
MarketBeat·23d ago
News Placeholder
Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives Average Recommendation of "Hold" from Brokerages
Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Get Free Report) have earned a consensus recommendation of "Hold" from the five analysts that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a b...
MarketBeat·23d ago
<
1
2
...
>

Latest HRTX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.